Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways
On Oct. 22, 2025, Alkermes announced it would acquire Avadel for $18.50 cash per share plus a $1.50 contingent value right tied to an FDA approval for idiopathic hypersomnia, valuing the deal at up to $2.1 billion prnewswire.com. The all-cash offer represents roughly a 12% premium to Avadel’s recent trading range. Avadel CEO Greg Divis hailed the terms as “a compelling outcome for our shareholders” prnewswire.com, while Alkermes CEO Richard Pops said the deal is “a pivotal step” to accelerate Alkermes’ entry into the sleep-medicine market prnewswire.com. Avadel’s board and Alkermes’ board have approved the merger, which is expected to close in Q1 2026 pending regulatory and shareholder approval. The takeover news sent AVDL shares sharply higher. After opening Oct. 22 at about $17.87, the stock gained further in early trading. Avadel topped ~$18.40 intraday, well above its 200-day moving average marketbeat.com. As one observer noted, the stock “crossed above its 200-day moving average of $11.36” and traded at multi-month highs marketbeat.com. Overall, trading volume on Oct. 22 surged to roughly 6.8 million shares, indicating heavy investor interest.
